Fatostatin is primarily used in research settings to study lipid metabolism and its regulation. It inhibits the activation of SREBP (sterol regulatory element-binding proteins), which are key transcription factors involved in the synthesis of fatty acids and cholesterol. By blocking SREBP processing, Fatostatin effectively reduces lipogenesis, making it a valuable tool for investigating metabolic disorders such as obesity, fatty liver disease, and type 2 diabetes. It has also shown potential in cancer research, as some tumor cells rely on increased lipid synthesis for growth and survival. Fatostatin has demonstrated antiproliferative effects in certain cancer cell lines, including prostate, breast, and liver cancers, by disrupting lipid homeostasis and inducing cell cycle arrest or apoptosis. Additionally, Fatostatin is being explored for its antiviral properties, as lipid metabolism plays a role in the replication of some viruses, including hepatitis C and dengue virus. Its ability to modulate cellular lipid pathways makes it a candidate for host-directed antiviral therapies. Overall, Fatostatin serves as a critical pharmacological agent in metabolic research and has emerging roles in oncology and virology.